BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

April 25, 2017

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa trials by GBP 2 million (USD 2.6 million) while shaving six months of the time to complete the program. He explains how the company, which was originally GSK’s imaging center and was spun out in 2011, helps clients determine whether a candidate drug gets into the tissue, hits the right target at optimal levels by providing an end-to-end service in PET and MR imaging studies for drug development. Services include experimental design, radio-chemistry, preclinical and clinical imaging, analysis and reporting.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Article
Where to start: How to gain a foothold in the China biopharmaceutical market
Where to start: How to gain a foothold in the China biopharmaceutical market

The China pharmaceutical market has come of age. With record breaking investments in innovative companies, ...

Next Video
BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets
BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets

With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 mill...